GlassScriptPhysician profile
Randolph M Gamez
NPI 1215998885
$3,708.48
in general payments reported to CMS, 2019-2025
26 companies · $561 in 2025
The $561 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $676 · 2020: $230 · 2021: $516 · 2022: $813 · 2023: $670 · 2024: $243 · 2025: $561.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,429 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,428.58 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $770.11 | 2019-2025 | Mounjaro, Zepbound, Kisunla |
| Amarin Pharma, INC. | $310.89 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $303.49 | 2019-2025 | Breztri, Farxiga |
| Novo Nordisk INC | $302.91 | 2019-2025 | Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $298.56 | 2019-2025 | Verquvo, Belsomra, Steglujan |
| Sanofi-Aventis U.S. LLC | $229.20 | 2019-2023 | |
| Pfizer INC. | $202.52 | 2019-2025 | |
| Glaxosmithkline, LLC. | $196.96 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Exact Sciences Corporation | $155.26 | 2023-2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $141.59 | 2019-2023 | |
| Abbvie INC. | $133.45 | 2022-2023 | |
| Astellas Pharma US INC | $104.53 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $87.51 | 2019-2025 | Jardiance |
| Nevro Corp. | $75.37 | 2022 | |
| Janssen Pharmaceuticals, INC | $70.68 | 2019-2023 | Xarelto |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $67.09 | 2023-2025 | Dexcom G6 Transmitter |
| Esperion Therapeutics, INC. | $59.43 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.86 | 2019-2022 | |
| Amgen INC. | $25.03 | 2019 | |
| Urovant Sciences INC | $24.80 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $21.46 | 2023 | Rexulti |
| Sumitomo Pharma America, INC. | $20.10 | 2025 | Gemtesa |
| Lundbeck LLC | $18.20 | 2024 | Rexulti |
| Vanda Pharmaceuticals INC. | $16.24 | 2021 | |
| Strongbridge US INC. | $15.33 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.91 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randolph Gamez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.